Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProQuad with concomitant MenACWY vaccine in healthy toddlers
2014-004694-16Phase 3
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of varicella virus vaccine and Meningococcal A, C, Y and W-135 conjugate vaccine in meningococcal disease, measles, mumps and 2 more (2 arms), sponsored by Novartis. Primary endpoint: Percentages of subjects with a seroresponse to measles, mumps, rubella and varicella following concomitant administration of MMRV vaccine with MenACWY-CRM vaccine.
02
Drugs
varicella virus vaccineMeningococcal A, C, Y and W-135 conjugate vaccine
03
Conditions
meningococcal diseasemeaslesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2014-004694-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004694-16.